Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.…
Rigel to Present at the Jefferies Global Healthcare Conference in London
Rigel Pharmaceuticals (NASDAQ: RIGL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 172 employees.
The shares were at 40.09 USD on 20 November 2026, up 11.0% over 52 weeks. Its 52-week range is 24.95 USD to 52.60 USD: the price is 23.8% below the high and 60.7% above the low.
At a market capitalisation of 754.89M USD, it trades at 2.5 times trailing earnings and 8.4 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 92% for RIGL.
Rigel Pharmaceuticals reports return on equity of 93.8%, an operating margin of 26.3% and revenue up 16.5% year over year.
It holds more cash than debt, a net cash position of 91.51M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 64.40 USD is 60.6% above the current price. The next earnings report is expected on 2 March 2027.